September 12th 2025
Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.
September 11th 2025
September 9th 2025
September 8th 2025
Impressions of MARIPOSA Overall Survival and Potential Impact in Current SOC
April 11th 2025Panelists discuss how the significant overall survival (OS) benefit demonstrated by the new combination therapy (amivantamab-lazertinib) compared with standard monotherapy makes it a preferred treatment option for most patients despite a slightly increased toxicity and time commitment.
Brief Overview of Current Treatment Landscape for 1L EGFRm NSCLC
April 11th 2025Panelists discuss how the treatment landscape for EGFR-mutated lung cancer has evolved, with 3 strong options now available, including single-agent osimertinib and 2 combinations: osimertinib plus chemotherapy (FLAURA2) and amivantamab plus lazertinib (MARIPOSA), with the latter showing significant overall survival benefits.
Evaluating ALK Inhibitors in Treatment Sequencing and Testing
Dr. Garon discusses the circumstances that might lead him to switch a patient with ALK+ NSCLC from another ALK inhibitor to lorlatinib.
Treatment Strategies in Disease Progression in ALK+ NSCLC
Dr. Kim discusses her approach to selecting the next treatment for patients with ALK+ NSCLC who progress on lorlatinib, including the key factors she considers in making this decision.
Patient Factors Considered when Choosing Treatment Selection
Dr. Garon explains his approach to choosing between different ALK inhibitors for ALK+ NSCLC, outlining the factors that guide his selection and when he might prefer alectinib, lorlatinib, or brigatinib.